1	A Discernable Increase in the Severe Acute Respiratory Syndrome
2	Coronavirus 2 R.1 Lineage Carrying an E484K Spike Protein Mutation in
3	Japan
4	
5	Running Title: Increasing R.1 lineage-related COVID-19 cases
6	
7	Authors:
8	Tsuyoshi Sekizuka, Kentaro Itokawa, Masanori Hashino, Kazuhiro Okubo, Asami Ohnishi,
9	Keiko Goto, Hiroyuki Tsukagoshi, Hayato Ehara, Ryohei Nomoto, Makoto Ohnishi, Makoto
10	Kuroda, Virus Diagnosis Group (NIID Toyama) and COVID-19 Genomic Surveillance Network
11	in Japan (COG-JP).
12	
13	Affiliations:
14	Pathogen Genomics Center, National Institute of Infectious Diseases, Shinjyuku, Tokyo, Japan
15	(T. Sekizuka, K. Itokawa, M. Hashino, M. Ohnishi, M. Kuroda)
16	Hokkaido Institute of Public Health, Hokkaido, Japan (K. Okubo)
17	Sapporo City Institute of Public Health, Hokkaido, Japan (A. Ohnishi)
18	Ibaraki Prefectural Institute of Public Health, Ibaraki, Japan (K. Goto)

19 Gunma Prefectural Institute of Public Health and Environmental Sciences, Gunma, Japan (H.

20 Tsukagoshi)

21 Saitama Prefectural Institute of Public Health, Yoshimi, Saitama, Japan (H. Ehara)

22 Kobe Institute of Health, Kobe, Hyogo, Japan (R. Nomoto)

23

Keywords: SARS-CoV-2, COVID-19, spike protein, E484K, R.1, mutation of concern, immune
escape, spatiotemporal distribution

26

27 Abstract—50 words

Three COVID-19 waves in Japan have been characterized by the presence of distinct PANGO lineages (B.1.1. 162, B.1.1.284, and B.1.1.214). Recently, in addition to the B.1.1.7 lineage, which shows 25% abundance, an R.1 lineage carrying the E484K mutation in the spike protein was found to show up to 40% predominance.

32

33 Text—704

As of March 31, 2021, Japan reported 475,043 cases and 9,175 deaths due to coronavirus disease (COVID-19), some of which were caused by variants of concern (VOCs). We conducted genome surveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with support from local public health centers or laboratory institutes (*1,2*) and five airport quarantine stations (Narita, Haneda, Nagoya, Kansai, and Fukuoka airports) (*3*). During the surveillance, we

39	monitored several VOCs of the PANGO lineage, namely B.1.1.7 (501Y.V1), B.1.351 (501Y.V2),
40	and P.1 (501Y.V3) (4), which have emerged in the past months in all countries. As of March 31,
41	2021, a notable increase in imported VOC cases has been identified at the airport (123 cases) and
42	domestic (678 cases) quarantines. COG-JP has been monitoring the prevalence of PANGO
43	lineages consistently, from the first COVID-19 case (January 15, 2021) up to recent cases
44	(March 6, 2021) [≥29 kb genome in size; in total, 28,350 isolates have been deposited in the
45	Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database (Appendix Table
46	1)]. The study protocol was approved by the National Institute of Infectious Diseases, Japan
47	(approval no. 1091). The ethics committee waived the written consent requirement for research
48	on the viral genome sequence.
49	We have found notable distribution of the PANGO lineage during each COVID-19 wave.
50	Specifically, B.1.1.162, B.1.1.284, and B.1.1.214 were predominant during the first, second, and
51	third waves, respectively (Figure 1). After the first wave (March to April 2020), an effort to
52	monitor airport quarantine was initiated; this measure was successful in reducing the numbers of
53	imported cases (3). Domestic lineages (B.1.1.284 and B.1.1.214), which may have been derived
54	phylogenetically from B.1.1.162 during the first wave, were predominant during the second
55	wave (July to September 2020). However, this was not the case for the other imported lineages.
56	Moreover, B.1.1.214 was the predominant lineage during the peak of the third wave (October
57	2020 to January 2021) (Figure 1).
58	Recently, a new R.1 lineage carrying the spike protein mutation E484K has been detected in
59	< 5% to $> 37.6%$ of all COVID-19-positive cases; within a span of six weeks (mid-January to
60	early March 2021), there has been a sharp increase in the cases (Figure 1). The spatiotemporal
61	distribution of the PANGO lineage showed that the R.1 cases appear to be predominant in the

Kanto and the northern Tohoku area. Our study, therefore, highlights the region-specific 62 transmission of COVID-19. Indeed, B.1.1.7 cases have been especially predominant in the 63 Kansai area; however, data from the ongoing surveillance of other VOCs will be required to 64 confirm the extensive transmission of B.1.1.7 across Japan. 65 As a notable feature of VOCs, the B.1.1.7 variant is susceptible to neutralizing antibodies 66 67 elicited by vaccines using the ancestral spike protein (5). However, there is a greater concern about the other immune evasion mutations, such as the E484K (Glu484 \rightarrow Lys) mutation in the 68 69 spike (S) protein that is found in the B.1.351 (501Y.V2) variant that emerged in South Africa and 70 the P.1 (501Y.V3) variant in Brazil (6). Indeed, E484K could be a pivotal amino acid substitution with potential for mediating immune escape. Thus far, B.1.1.318, B.1.525, R.1, R.2, and P.2 have 71 been reported as variants carrying the E484K single mutation on the receptor-binding domain. 72 R.1 has been mostly identified in USA (first found on October 24, 2020) and Japan (first found 73 on November 30, 2020). In fact, phylogenetic analysis indicated that both R.1 isolates were 74 75 highly similar. Thus, the Japanese R.1 isolate might have originated from the R.1 isolate from USA. Conversely, it is possible that the isolates in both countries have been imported from an 76 77 uncharacterized source in another country, where a potential common ancestor (B.1.1.316) was 78 circulating (Appendix Figure 1).

In conclusion, although VOCs have a marked impact on the number of cases and the
severity of COVID-19 across many countries, mutants of concern carrying pivotal mutations
should not be disregarded if the latent distribution has been found across the community. We
should pay more attention to such potential VOCs to avoid the emergence of mutants of concern.
Based on the current epidemiological situation in Japan, with an increase in the circulation of
more transmissible lineages, immediate, strong, and decisive public health interventions such as

- contact-tracing, strict quarantine monitoring, and comprehensive real-time genome surveillance
 have become essential for containment of COVID-19 clusters.
- 87

88 Acknowledgments

- 89 This work was supported by a Grant-in-Aid from the Japan Agency for Medical Research, and
- 90 the Development Research Program on Emerging and Re-emerging Infectious Diseases
- 91 [JP20fk0108103 and JP19fk0108104, respectively]. We would like to thank all researchers who
- 92 deposited and shared genomic data on GISAID (Column H-J in Appendix Table 1). The
- 93 collaborators are listed in Appendix Table 2.

94

95 Author Bio

- 96 Dr. Sekizuka is the chief of the Pathogen Genomics Center, National Institute of Infectious
- 97 Diseases, Japan. He developed bioinformatics tools to elucidate the transmission dynamics,
- 98 surveillance, and control of infectious diseases based on pathogen genomics.

99

100 **References**

- Itokawa K, Sekizuka T, Hashino M, Tanaka R, Kuroda M. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS One. 2020;15:e0239403.
- Sekizuka T, Itokawa K, Hashino M, Kawano-Sugaya T, Tanaka R, Yatsu K, et al. A
 genome epidemiological study of SARS-CoV-2 introduction into Japan. mSphere. 2020;5.
- Sekizuka T, Itokawa K, Yatsu K, Tanaka R, Hashino M, Kawano-Sugaya T, et al.
 COVID-19 genome surveillance at international airport quarantine stations in Japan. J Travel
 Med. 2021;28.
- 4. Fujino T, Nomoto H, Kutsuna S, Ujiie M, Suzuki T, Sato R, et al. Novel SARS-CoV-2
 variant in travelers from Brazil to Japan. Emerg Infect Dis. 2021;27.

- 111 5. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant
- B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. CellHost Microbe. 2021.
- 6. Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern.
 Science. 2021;371:1103-4.
- 7. Julia L. Mullen GT, Alaa Abdel Latif, Manar Alkuzweny, Marco Cano, Emily Haag,
 Jerry Zhou, Mark Zeller, Nate Matteson, Kristian G. Andersen, Chunlei Wu, Andrew I. Su,
 Karthik Gangavarapu, Laura D. Hughes, and the Center for Viral Systems Biology
 outbreak.info. 2020. https://outbreak.info/
- 8. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: realtime tracking of pathogen evolution. Bioinformatics. 2018;34:4121–3.

122

- Address for correspondence: Makoto Kuroda, Pathogen Genomics Center, National Institute
- of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan; email:
- 125 <u>makokuro@niid.go.jp</u>

126

127



129 Figure 1. A spatiotemporal analysis of the SARS-CoV-2 PANGO lineage in Japan.

- 130 A) Numbers and B) abundance ratios of whole-genome sequences of SARS-CoV-2 isolates from
- domestic COVID-19-positive patients in Japan (n = 28,965) were assigned as per the PANGO
- 132 lineage definition (2021/02/21 version). Top 20 PANGO lineages have been highlighted as per
- the colors on the right. C) Area-specific lineage percentage is displayed using colored pie charts
- (shown in panel A and B) from December 2020 to February 2021.

135 Appendix Table 1.

- 136 Collaboration with local public health institutes and airport quarantines under the COG-JP have
- 137 been indicated. All SARS-CoV-2 complete genome sequences that we determined and other
- deposited sequences identified in Japan were retrieved from the GISAID (n = 28,965). COG-JP,
- 139 COVID-19 genomic surveillance network in Japan; GISAID, Global Initiative on Sharing All
- 140 Influenza Data; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
- 141

142 Appendix Table 2.

- 143 Collaboration between local public health institutes and the COVID-19 genomic surveillance
- 144 network in Japan (COG-JP) has been shown.

145

A)



B)

Summary As of 3 April 2021, 1,60	00 sequi	ences in the R.1 lineage l	nave been dete	cted since
he lineage was identi	fied:	R.1 found	when fo	ound**
ocation 😈	total	cumulative prevalence*	first	last
Japan	860	6%	30 Nov 2020	17 Mar 2021
United States	546	< 0.5%	24 Oct 2020	24 Mar 2021
			6 Jan 2021	17 Mar 2021
Worldwide	1,600	< 0.5%	24 Oct 2020	24 Mar 2021
		< 0.5%	4 Feb 2021	23 Mar 2021
California, United States		< 0.5%	24 Dec 2020	6 Mar 2021



Appendix Figure 1. Summary of SARS-CoV-2 R.1 lineage (April 3rd, 2021) A) The R.1 lineage has a mutation of concern. The R.1 lineage carries the E484K mutation in the S protein; common genetic features are highlighted above the schematic representation of the SARS-CoV-2 genome structure. B) Current information on the number of cases, country, and first detection date for the R.1 lineage (7). C) Phylogenetic analysis of the R.1 lineage by Nextstrain analysis, along with the B.1.1.316 lineage which is the most recent common ancestor (8).